AVP and Hyponatremia: This strategy would still likely attenuate a rise in serum osmolality and subsequent AVP secretion (Cheuvront and Kenefick 2014), thereby reducing an important mechanism that is likely involved in renal injury (Bragadottir et al. 2009; García-Arroyo et al. 2017; Roncal-Jimenez et al. 2017; Mansour et al. 2019), while also minimising performance decrements (James et al. 2017, 2019; Funnell et al. 2019), but with a lower risk of exercise-associated hyponatremia.